Core Viewpoint - Company completed the placement agreement conditions and successfully placed 9.23 million shares at a price of HKD 17.01 per share, raising approximately HKD 157 million in total proceeds [1] Fund Allocation - Approximately 60% of the net proceeds from the placement, around HKD 93 million, will be used for the research and commercialization of existing pipelines [1] - About 30% of the net proceeds, approximately HKD 46.5 million, will be allocated to enhance internal research capabilities and expand the product portfolio [1] - The remaining 10% of the net proceeds, around HKD 15.5 million, will be utilized for working capital and general corporate purposes [1]

Group 1 - The company announced that all conditions of the placement agreement have been met and completed on August 4, 2025 [1] - The placement agent successfully placed a total of 9.23 million shares at a price of HKD 17.01 per share to no less than six subscribers [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 浙江同源康醫藥股份有限公司 呈交日期： 2025年8月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02410 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據1933年美國證券法（經修訂）登記 或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將僅以 招股章程的方式進行，該招股章程可向發行人或出售證券持有人取得，並載有發行人及管理層 的詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 完成根據一般授權配售新H股 配售代理 完成配售 本公司欣然宣佈，配售協議所載的所有條件已獲達成並於2025 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上巿股份 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,608,000 | RMB | | 1 | RMB | | 4,608,000 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 4,608,000 | RMB | | 1 | RMB | | 4,608,000 | 本月底法定/註冊股本總額： RMB 370,835,818 公司名稱: 浙江同源康醫藥股份有限公司 (於中華人民共 ...

Group 1 - The Hang Seng Biotechnology Index (HSHKBIO) has seen a strong increase of 1.88%, with notable gains from constituent stocks such as MicroPort Medical (00853) up 8.63%, and Stone Pharmaceutical Group (01093) up 7.40% [1] - The Hang Seng Biotechnology ETF (513280) has risen by 3.00%, marking its third consecutive increase, with a latest price of 1.34 HKD and a weekly cumulative increase of 8.89% [1] - The trading volume for the Hang Seng Biotechnology ETF was active, with a turnover of 34.45% and a transaction value of 161 million HKD, indicating strong market participation [1] Group 2 - The Hang Seng Biotechnology ETF has experienced a significant increase in shares, growing by 2 million shares over the past week, ranking in the top third among comparable funds [2] - The ETF has seen continuous net inflows over the last three days, with a peak single-day net inflow of 3.83 million HKD, totaling 8.73 million HKD in net inflows [2] Group 3 - Over the past year, the net value of the Hang Seng Biotechnology ETF has increased by 130.59%, ranking 3rd out of 122 QDII equity funds, placing it in the top 2.46% [3] - WuXi Biologics announced the construction of a modular biomanufacturing facility in Singapore, which is part of a strategic collaboration with Pharmadule Morimatsu [3] - The latest report from Zhongyin Securities suggests focusing on three main lines: 1) sectors with stable growth such as medical devices and pharmaceuticals, 2) the CXO sector and medical equipment expected to see a turnaround, and 3) innovative fields related to national medical insurance negotiations [3] Group 4 - The Hang Seng Biotechnology ETF (513280) is highlighted as the only ETF tracking the Hang Seng Biotechnology Index to have received net inflows this year, with the lowest management fee of 0.15% per year among Hong Kong pharmaceutical ETFs [4]

Group 1 - The core point of the news is that Tongyuan Kang Pharmaceutical-B (02410) has announced a placement agreement to issue 9.23 million shares at a price of HKD 17.01 per share, which represents a discount of approximately 19% compared to the last closing price of HKD 21.0 on July 28, 2025 [1][2] - The placement will result in an increase of approximately 2.46% in the total issued H-shares and about 2.43% in the total issued shares of the company [1] - The expected total proceeds from the placement are approximately HKD 157 million, with a net amount of about HKD 155 million after deducting commissions and related costs [2] Group 2 - The company plans to allocate approximately 60% of the net proceeds from the placement for research and commercialization of its existing pipeline [2] - About 30% of the net proceeds will be used to enhance internal research capabilities and expand the product portfolio [2] - The remaining 10% of the net proceeds will be allocated for working capital and general corporate purposes [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國境內，或在刊發或派發本公告屬違法的任何其他 司法權區內刊發或派發。本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之 邀請或要約。 本公告不構成亦不屬於在美國境內或有關要約屬違法的任何其他司法權區出售證券的任何要約 或招攬購買或認購證券的一部分。本公告所述的本公司股份並無亦不會根據1933年美國證券法 （經修訂）（「美國證券法」）登記，且除非根據美國證券法登記規定進行登記或獲豁免遵守該等登 記規定，否則不得於美國境內提呈發售或出售。本公司無意根據美國證券法登記本公告內所指 之任何證券，或在美國境內進行證券之公開發售。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 根據一般授權配售新H股 配售代理 配售事項 於2025年7月28日（交易時段後），本公司與配售代理訂立配售協 ...

Group 1 - The stock price of Valiant Biotech-B (09887.HK) increased by 113% [1] - The stock price of China Antibody-B (03681.HK) rose by 8.37% [1] - The stock price of Lepu Biopharma-B (02157.HK) went up by 5.64% [1] - The stock price of Tongyuan Kang Pharmaceutical-B (02410.HK) increased by 3.81% [1]

Core Viewpoint - The company announced that three of its self-developed clinical products, TY-302, TY-2699a, and TY-0540, have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) conference, with detailed data to be published in the official ESMO journal, "Annals of Oncology" [1][2]. Group 1: Product Details - TY-302 is a potent, selective oral CDK4/6 inhibitor developed for treating advanced solid tumors such as breast and prostate cancer. It targets CDK4/6 to inhibit the phosphorylation of Rb, preventing cancer cell proliferation. Preclinical studies indicate lower gastrointestinal side effects and more controllable hematological toxicity compared to the leading CDK4/6 inhibitor, palbociclib. Phase I clinical data show significant efficacy and good safety when combined with tamoxifen for HR+/HER2- advanced breast cancer patients [1]. - TY-2699a is a selective CDK7 inhibitor aimed at treating advanced/metastatic solid tumors. Preclinical studies confirm its ability to precisely inhibit cancer cell growth at doses that do not affect normal cells. Initial clinical data demonstrate excellent safety and preliminary efficacy at similar dose levels. The data presented is from a Phase I multicenter monotherapy dose-escalation trial, with ongoing expansion trials for triple-negative breast cancer (TNBC) [2]. - TY-0540 is a selective CDK2 inhibitor intended for treating breast cancer, ovarian cancer, and other solid tumors. It shows strong inhibitory effects on key targets such as CDK2/CycA2 and CDK2/CycE1, while also exhibiting activity against related targets CDK4/CycD1 and CDK6/CycD3. Both preclinical and clinical studies indicate significant inhibitory effects and good safety profiles in various solid tumors, including models resistant to palbociclib. The data presented is from a Phase I multicenter open-label clinical trial, with ongoing Phase Ib/II studies [2].